Arbutus Biopharma CORP 8-K filings

Arbutus Biopharma reported Q2 2026 results, highlighting a $178M payment from Moderna settlement, progress on imdusiran's Phase 2b trial, and plans for a capital return to shareholders.

Arbutus Biopharma announced receipt of $178M from Moderna settlement, initiated patent lawsuits against Pfizer/BioNTech, and plans to return up to $230M to shareholders.

Arbutus Biopharma Corporation shareholders approved the 2026 Omnibus Share and Incentive Plan at the Annual Meeting, replacing previous plans and authorizing 16.3 million common shares.

Arbutus Biopharma announced strong first quarter 2026 financial results, driven by a significant license revenue from the Genevant settlement with Moderna, alongside positive corporate updates including FDA Fast Track designation for imdusiran.

Arbutus Biopharma Corporation announced that the U.S. FDA has granted Fast Track designation for its investigational therapy, imdusiran, for the treatment of chronic hepatitis B.

Arbutus Biopharma announced a significant $2.25 billion global settlement with Moderna for LNP patent infringement, alongside its fourth quarter and full year 2025 financial results.

A U.S. District Court ruled that Arbutus's patent infringement claims against Moderna for most COVID-19 vaccine doses can proceed in district court, while limiting claims under the doctrine of equivalents.

Arbutus Biopharma's European patent EP 2279254 was revoked by the EPO Board of Appeal, impacting some ongoing litigation but not others.

Arbutus Biopharma presented an update on its ongoing patent infringement lawsuits against Moderna, Pfizer, and BioNTech regarding their COVID-19 vaccines' use of patented lipid nanoparticle technology.

Arbutus Biopharma reported strong Q3 2025 financial results, positive imdusiran clinical data, and favorable progress in its LNP patent litigation against Moderna and Pfizer/BioNTech.

Arbutus Biopharma announced the acceptance of four abstracts, including a 'Poster of Distinction' for AB-101, for presentation at The Liver Meeting 2025.

Arbutus Biopharma and Genevant Sciences received a favorable claim construction ruling in their patent infringement lawsuit against Pfizer and BioNTech regarding mRNA vaccine technology.

Arbutus Biopharma reported a net income of $2.5 million for Q2 2025, driven by deferred revenue recognition, alongside board appointments and updates on its LNP patent litigation.

Arbutus Biopharma Corporation has reacquired full global rights to its lead chronic hepatitis B compound, imdusiran, from Qilu Pharmaceutical without payment, and announced the formation of a new Scientific Advisory Board comprised of leading experts in the field.

Arbutus Biopharma Corporation announced that its shareholders approved all proposals at the 2025 Annual General Meeting, including the election of five director nominees, the non-binding advisory vote on executive compensation, and the appointment of Ernst & Young LLP as independent auditors.

Arbutus Biopharma announces Q1 2025 financial results and provides a corporate update, highlighting functional cures in chronic hepatitis B patients and progress with its oral PD-L1 inhibitor.

Arbutus Biopharma announces the presentation of clinical trial data at the EASL Congress 2025, highlighting the potential of imdusiran and AB-101 in treating chronic hepatitis B.

Arbutus Biopharma announces the acceptance of five abstracts, including one late-breaker, for presentation at the European Association for the Study of the Liver (EASL) Congress 2025.

Arbutus Biopharma reports the departures of its Chief Medical Officer and Chief Financial Officer, along with updates on their separation agreements and a shift in the trial date for their patent lawsuit against Moderna.

Arbutus Biopharma announced its Q4 and year-end 2024 financial results, a corporate restructuring including a workforce reduction, and provided an update on its pipeline and litigation efforts.

Arbutus Biopharma and Genevant Sciences are intensifying their legal battle against Moderna by filing international lawsuits to protect their lipid nanoparticle (LNP) technology.

Arbutus Biopharma announces a complete change of its board of directors and appoints Lindsay Androski as the new CEO, effective immediately.

Arbutus Biopharma is advancing its hepatitis B program with a planned Phase 2b trial for imdusiran, reporting positive clinical data and a strong financial position.

Arbutus Biopharma reports significant functional cure rates in chronic hepatitis B patients using imdusiran combined with interferon, and also shows positive results with the addition of nivolumab in a separate trial.

Arbutus Biopharma announced its third quarter 2024 financial results, provided a corporate update, and highlighted progress in its clinical trials for chronic hepatitis B virus (cHBV) treatments.

Arbutus Biopharma will present clinical data on its RNAi therapeutic, imdusiran, at the AASLD Liver Meeting in November, including two late-breaking posters from Phase 2a trials.

Arbutus Biopharma has amended its employment agreement with its retiring Chief Scientific Officer, Michael J. Sofia, to clarify his post-retirement activities and bonus eligibility.

Arbutus Biopharma and Genevant Sciences have filed a stipulation to extend the trial date in their patent infringement lawsuit against Moderna, moving the potential start to September 24, 2025.

Arbutus Biopharma is focusing on its lead HBV candidate, imdusiran, leading to a workforce reduction and extended cash runway.

Arbutus Biopharma's combination therapy of imdusiran and VTP-300 shows significant reduction in HBsAg levels in chronic hepatitis B patients, with a high percentage achieving NA therapy discontinuation criteria.